Sprache auswählen
SHP-2
SHP-2 Molekülinformation
| Englischer Name | Src homology phosphotyrosyl phosphatase 2 | Anzahl der inverkehr gebrachten Arzneimittel | 0 |
| Anzahl der klinischen Arzneimittel | 21 | Target-Alias | Protein Tyrosine Phosphatase Non-Receptor Type 11，SHP-2，PTP2C，Protein-tyrosine phosphatase 2C，PTP-2C，PTP-1D，SH-PTP3，PTPN11，Protein-Tyrosine Phosphatase 1D，SH-PTP2，EC:3.1.3.48，Noonan Syndrome 1，EC 3.1.3.48，METCDS，SHPTP2，BPTP3，JMML，SHP2，CFC，NS1，Protein Tyrosine Phosphatase， Non-Receptor Type 11，Tyrosine-Protein Phosphatase Non-Receptor Type 11 |
| Höchste Forschungs- und Entwicklungsphase | Phase 3 Clinical | ||
| Englischer Name | Src homology phosphotyrosyl phosphatase 2 |
| Target-Alias | Protein Tyrosine Phosphatase Non-Receptor Type 11，SHP-2，PTP2C，Protein-tyrosine phosphatase 2C，PTP-2C，PTP-1D，SH-PTP3，PTPN11，Protein-Tyrosine Phosphatase 1D，SH-PTP2，EC:3.1.3.48，Noonan Syndrome 1，EC 3.1.3.48，METCDS，SHPTP2，BPTP3，JMML，SHP2，CFC，NS1，Protein Tyrosine Phosphatase， Non-Receptor Type 11，Tyrosine-Protein Phosphatase Non-Receptor Type 11 |
| Anzahl der inverkehr gebrachten Arzneimittel | 0 |
| Anzahl der klinischen Arzneimittel | 21 |
| Höchste Forschungs- und Entwicklungsphase | Phase 3 Clinical |
SHP-2 Produktliste
- Attribut
Protein (1)
- Produktbibliothek
Online (1)
- Spezies
Human (1)
- Etikett
His Tag (1)
- Marker
Unconjugated (1)
| Produktnummer | Spezies | Expressionssystem | Produktbeschreibung | Proteinstruktur | Reinheit | Eigenschaften | Vorbestellen/Bestellen |
|---|---|---|---|---|---|---|---|
SH2-H5248 |  Human | E. coli | Human SHP-2 Protein, His Tag |  |  |  In den Warenkorb legen |
Gesamtmenge1
- 1
SHP-2 Molekülhintergrund
SHP-2, a cytoplasmic SH2 domain containing protein tyrosine phosphatase, is involved in the signaling pathways of a variety of growth factors and cytokines. SHP-2 takes key role in transducing signal relay from the cell surface to the nucleus, and is a important intracellular regulator in mediating cell proliferation and differentiation.
SHP-2 Molekülalias
SHP-2
Klinische Arzneimittelinformation
| Englischer Name | Forschungscode | Forschungsphase | Firma | Indikationen | Klinische Studie |
|---|---|---|---|---|---|
| Sitneprotafib | JAB-3312; AST24082 | Phase 3 Clinical | Jacobio Pharmaceuticals Co Ltd | Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Colorectal Neoplasms; Esophageal Squamous Cell Carcinoma; Solid tumours; Squamous Cell Carcinoma of Head and Neck | Details |
| JAB-3068 | JAB-3068 | Phase 2 Clinical | Abbvie Inc, Jacobio Pharmaceuticals Co Ltd | Carcinoma, Adenoid Cystic; Carcinoma, Non-Small-Cell Lung; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Head and Neck Neoplasms; Lymphoma; Solid tumours; Squamous Cell Carcinoma of Head and Neck | Details |
| Vociprotafib | RMC-4630; SAR-442720 | Phase 2 Clinical | Revolution Medicines Inc, Sanofi | Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Neoplasm Metastasis; Neoplasms; Pancreatic Neoplasms; Solid tumours | Details |
| Batoprotafib | TNO-155 | Phase 2 Clinical | Novartis Pharma Ag | Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Esophageal Squamous Cell Carcinoma; Gastrointestinal Stromal Tumors; Hepatic Insufficiency; Lung Neoplasms; Melanoma; Neoplasm Metastasis; Neoplasms; Renal Insufficiency; Solid tumours; Squamous Cell Carcinoma of Head and Neck | Details |
| GH-21 | GH 21005; GH-21; HBI-2376 | Phase 2 Clinical | Suzhou Genhouse Bio Co Ltd | Carcinoma, Non-Small-Cell Lung; Colonic Neoplasms; Colorectal Neoplasms; Head and Neck Neoplasms; Neoplasms; Pancreatic Neoplasms; Solid tumours | Details |
| BR-790 | BR-790 | Phase 2 Clinical | Jiangxi Qingfeng Pharmaceutical Industry Co Ltd | Carcinoma, Non-Small-Cell Lung; Neoplasms; Solid tumours | Details |
| ERAS-601 | ERAS-601 | Phase 2 Clinical | NiKang Therapeutics Inc | Chordoma; Leukemia, Myeloid, Acute; Solid tumours | Details |
| BBP-398 | IACS-15509; BBP-398; IACS-13909; BMS-986466 | Phase 2 Clinical | Bridgebio Pharma Inc, The University Of Texas MD Anderson Cancer Center | Carcinoma, Non-Small-Cell Lung; Solid tumours | Details |
| Migoprotafib | RLY-1971; GDC-1971; RO-7517834; RG-6433 | Phase 1 Clinical | Relay Therapeutics Inc | Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Solid tumours | Details |
| A-380 | A-380 | Phase 1 Clinical | Klus Pharma Inc, Shandong Kelun Phaemaceutical Co Ltd | Neoplasms | Details |
| KYHY-2303 | KYHY2303; KYHY-2303 | Phase 1 Clinical | Jiangsu Kanion Pharmaceutical Co Ltd, Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences | Hematologic Neoplasms | Details |
| RG-001 | RG001; RG-001 | Phase 1 Clinical | Rudong Ringene Pharmaceuticals Co Ltd, Shanghai Lingji Biological Technology Co Ltd | Neoplasms | Details |
| HS-336 | HS336; HS-336 | Phase 1 Clinical | Zhejiang Hisun Pharmaceutical Co Ltd | Solid tumours | Details |
| HMPL-415S1 | HMPL-415S1 | Phase 1 Clinical | Solid tumours | Details | |
| PH-005 | PH005; PH-005 | Phase 1 Clinical | Suzhou Puhe Pharmaceutical Technology Co Ltd | Solid tumours | Details |
| BPI-442096 | Phase 1 Clinical | Betta Pharmaceuticals Co Ltd | Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Pancreatic Neoplasms; Solid tumours | Details | |
| HS-10381 | HS-10381 | Phase 1 Clinical | Jiangsu Hansoh Pharmaceutical Group Co Ltd | Solid tumours | Details |
| ET-0038 | ET-0038 | Phase 1 Clinical | Etern BioPharma (Shanghai) Co Ltd | Solid tumours | Details |
| PF-07284892 | ARRY-558; PF-07284892 | Phase 1 Clinical | Pfizer Inc | Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Colorectal Neoplasms; Solid tumours | Details |
| ICP-189 | ICP-189 | Phase 1 Clinical | InnoCare Pharma Ltd | Carcinoma, Non-Small-Cell Lung; Solid tumours | Details |
| SH-3809 | SH3809 | Phase 1 Clinical | Nanjing Sanhome Pharmaceutical Co Ltd | Solid tumours | Details |
- Molekülinformation
- Produktliste
- Klinische Arzneimittelinformation
Teilen auf:
Online-Nachricht
Kontaktieren Sie uns
BettinastraBe 30, 60325 Frankfurt am Main